The Pharma Data

DECEMBER 22, 2020

Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. “In Perlmutter, President, Merck Research Laboratories. “We

Therapies 52

Therapies Research Laboratories Engineering Laboratories 52

The Pharma Data

JUNE 7, 2023

We are delighted that PREVYMIS is now approved to help prevent CMV disease in adult kidney transplant patients at high risk,” said Dr. Elizabeth Rhee, vice president, global clinical development, Merck Research Laboratories. “At Source link: [link]

FDA Approval 40

FDA Approval FDA Disease Research Laboratories 40

The Pharma Data

NOVEMBER 9, 2020

It is very clear that in this study, the addition of ipilimumab did not add clinical benefit but did add toxicity. Merck and Eisai are committed to working together to continue to explore the potential of the KEYTRUDA plus LENVIMA combination, particularly in areas of great unmet need such as renal cell carcinoma.”. “We

Research Laboratories 52

Research Laboratories Laboratories Treatment Therapies 52

The Pharma Data

AUGUST 31, 2021

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

SEPTEMBER 21, 2020

Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer at MSD Research Laboratories, said: “HRD is an important biomarker of advanced ovarian cancer that can inform how physicians in the EU treat this aggressive type of cancer. months versus 35.3 months with bevacizumab.

Research Laboratories 52

Research Laboratories Trials Treatment Laboratories 52

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

JULY 29, 2021

About Loxo Oncology at Lilly Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. For more information, please visit www.kumquatbiosciences.com. Source link: [link] nvestor.lilly.com/.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

The Pharma Data

JUNE 2, 2023

Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said, “It is imperative that we create new ways to treat advanced cancers and help improve patient outcomes by building on the current standard of care.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

SEPTEMBER 28, 2021

“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Importantly, this treatment regimen are often utilized in combination with different chemotherapy agents.

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. “Patients with stage III and IV melanoma can be at high risk of having their cancer recur or metastasize to other sites,” said Dr. Eric H.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

The Pharma Data

JUNE 1, 2022

Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization. Prior to Pfizer, Dr. Anderson worked at Merck Research Laboratories where she founded its prokaryotic bio-combinatorial engineering laboratory and initiated a bacterial vaccine program.

Vaccine 40

Vaccine Research Doctors Laboratories 40

The Pharma Data

APRIL 28, 2023

We strongly believe in the results of the PROpel trial, which demonstrated the clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”

FDA 40

FDA Trials Research Laboratories Treatment 40

The Pharma Data

APRIL 8, 2021

“Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Disease 52

Disease Therapies Research Laboratories Trials 52

The Pharma Data

MARCH 8, 2021

“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

MARCH 16, 2021

We are excited to embark on this partnership with Boehringer Ingelheim to identify potential therapeutic candidates and advance them to clinical development in order to help improve the lives of those affected by this serious mental health condition.”. The Lieber Institute for Brain Development. Weinberger, M.D.,

Licensing 52

Licensing Licensing Research Laboratories Pharmaceutical Companies 52

The Pharma Data

APRIL 28, 2023

We strongly believe in the results of the PROpel trial, which demonstrated a clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”

FDA 40

FDA FDA Approval Trials Treatment 40

The Pharma Data

AUGUST 7, 2020

Most importantly, we are continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly Research Laboratories in a partnership with AbCellera.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. He spent 27 years at Merck & Co.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52

The Pharma Data

NOVEMBER 22, 2020

“There is a real need to advance new treatment options for triple-negative breast cancer, an aggressive form of the disease,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, in July 2020.

FDA 52

FDA Licensing Licensing FDA Approval 52

The Pharma Data

NOVEMBER 11, 2021

Joerg Koglin, vice chairman, Global Clinical Development and Therapeutic Area Head, Cardiovascular for Merck Research Laboratories. The inauguration of the Phase 3 VICTOR study reflects our commitment to chancing fresh options for a habitual heart failure condition that affects further than 3 million people in theU.S.

Clinical Trials 40

Clinical Trials Hospitals Trials Research Laboratories 40

The Pharma Data

JUNE 25, 2021

Merck is continuing to study KEYTRUDA, in combination or as monotherapy, as well as other investigational products across multiple settings and stages of RCC including adjuvant and advanced or metastatic disease through our broad clinical development program, which includes over 20 clinical studies and more than 4,000 patients.

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

JULY 21, 2021

“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Treatment 52

Treatment Production Hospitals FDA Approval 52

The Pharma Data

JULY 18, 2021

That’s why we set out to develop a conjugate vaccine that includes pneumococcal serotypes that pose the greatest threat and elicits a strong immune response to each serotype covered,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

OCTOBER 19, 2020

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

APRIL 11, 2021

Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. Our approach centers on creating new oncology medicines that unequivocally work early in clinical development and will matter to patients.

Research 52

Research Treatment Therapies Trials 52

The Pharma Data

MARCH 15, 2022

“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

DNA 52

DNA Clinical Trials Trials Therapies 52

The Pharma Data

NOVEMBER 18, 2021

All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. mg daily (DOR/ISL) in HIV-1 virologically suppressed participants.

Clinical Trials 52

Clinical Trials Trials Treatment RNA 52

The Pharma Data

AUGUST 30, 2021

“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Treatment 52

Treatment Research Laboratories Trials Packaging 52

The Pharma Data

JULY 15, 2021

“These highly anticipated event-free survival results in this TNBC population build upon earlier findings from the KEYNOTE-522 trial and further support the potential use of KEYTRUDA in these patients,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories.

Therapies 52

Therapies Treatment Trials FDA 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Pharma Data

MARCH 5, 2021

Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. Our approach centers on creating new oncology medicines that unequivocally work early in clinical development and will matter to patients.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Therapies 52

The Pharma Data

OCTOBER 27, 2021

Gilead Lores, and Merck, known as MSD outside the United States and Canada, moment blazoned the launch of a Phase 2 clinical study assessing an investigational formerly-daily oral combination treatment authority of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral remedy.

Treatment 52

Treatment Clinical Trials Clinical Development Research Laboratories 52

The Pharma Data

NOVEMBER 19, 2020

Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. The company also announced the addition of Robin Patel to its clinical and scientific advisory board. Additionally, Raffaele Baffa was named chief medical officer of Ziopharm.

Laboratories 52

Laboratories Research Laboratories Organic Chemistry Science 52

The Pharma Data

MARCH 8, 2021

“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinical development, infectious diseases, Merck Research Laboratories. “We

Trials 52

Trials Clinical Trials Pharmacokinetics Research Laboratories 52

The Pharma Data

JULY 21, 2021

As part of our commitment to understanding the potential for our HIV medicines in a broad range of patients, we focused on the enrollment of diverse patient populations at risk for HIV, including women, who have one of the highest unmet needs in HIV prevention.”.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

APRIL 7, 2023

Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. Senior Vice President, Clinical Development, Oncology at Eisai Inc.

Trials 40

Trials Clinical Trials Treatment Therapies 40